Freenome (FRNM) Stock Price, News & Analysis

Company Overview

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at early stages. The company combines artificial intelligence, machine learning and multi-omic analysis of blood samples to identify biological signals associated with cancer, including signals from tumors and the immune system.

Freenome’s primary focus has been the development of noninvasive screening tests for colorectal cancer and other common cancers. Its platform is intended to support earlier detection through routine blood draws, with colorectal cancer screening among the company’s most advanced areas of development. The company’s tests and related technologies remain subject to clinical validation and applicable regulatory review.

Founded in 2014 and based in San Francisco, Freenome has conducted research and clinical-development activities primarily in the United States. The company has worked with healthcare, pharmaceutical and research organizations to advance its screening platform. Mike Nolan has served as Freenome’s chief executive officer; the company was originally founded by Gabe Otte.

Key Stats

• Today's Range: $11.80 to $12.72
• 50-Day Range: $11.56 to $17.11
• 52-Week Range: $9.97 to $17.50
• Volume: 301,179 shs
• Average Volume: 874,117 shs
• Market Capitalization: $1.32 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Moderate Buy

Freenome Stock Analysis - MarketRank™

Freenome scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Freenome has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Freenome has a consensus price target of $18.00, representing about 42.5% upside from its current price of $12.64.

Amount of Analyst Coverage

Freenome has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Freenome is -210.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.06% of the float of Freenome has been sold short.

Short Interest Ratio / Days to Cover

Freenome has a short interest ratio ("days to cover") of 3.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Freenome has recently increased by 100.39%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Freenome does not currently pay a dividend.

Dividend Growth

Freenome does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.29

News Sentiment

Freenome has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Freenome this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for FRNM on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Freenome insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.06% of the stock of Freenome is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Freenome has minimal institutional ownership at this time.

Company Calendar

• Today: 10/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FRNM
• CIK: 2017526
• Web: www.freenome.com
• Phone: (212) 284-2300
• Fax: N/A
• Employees: 378
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Freenome: $18.00
• High Price Target: $21.00
• Low Price Target: $17.00
• Potential Upside/Downside: +47.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $840 thousand
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2.70%
• Return on Assets: -0.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.20
• Quick Ratio: 0.20

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.09 per share
• Price / Cash Flow: 140.75
• Book Value: ($0.54) per share
• Price / Book: -22.59

Miscellaneous

• Outstanding Shares: 107,450,000
• Free Float: 83,744,000
• Market Cap: $1.31 billion
• Optionable: N/A
• Beta: 0.44